SOURCE: Cardima, Inc.

January 16, 2008 15:00 ET

Cardima Showcases Mapping and Ablation Products at the 13th International Boston Atrial Fibrillation Symposium

FREMONT, CA--(Marketwire - January 16, 2008) - Cardima, Inc. (OTCBB: CADM) today announced that the Company will attend and exhibit at the 13th International Boston Atrial Fibrillation Symposium, which will be held January 17-19, 2008 in Boston, Massachusetts. Cardima will participate and showcase its product initiatives and technologies for diagnosing arrhythmias and treating atrial fibrillation in its booth #622 during the symposium. In addition, Cardima's linear ablation system comprising the REVELATION® T-Flex ablation microcatheter and INTELLITEMP EP Energy Management Device will be highlighted in a presentation during the symposium by a noted physician speaker who is a leader in the AF ablation field.

Atrial fibrillation, the most common cardiac arrhythmia and a major concern for healthcare providers worldwide, is the focus of this symposium. Recent estimates are that over 2.5 million people in the U.S. have atrial fibrillation, of which 1 million are symptomatic yet do not respond well to drug therapy. Furthermore, about 200,000 new cases are diagnosed each year in the U.S. The organizers of this annual symposium have succeeded in bringing a stellar cast of international faculty and speakers, as well as technology providers, to converge and share rapidly evolving advances in knowledge about the mechanisms of and treatment options for this important public health challenge.

About Cardima

Cardima, Inc. has developed the PATHFINDER® and REVELATION® Series of diagnostic catheters, the INTELLITEMP® Energy Management Device, and the Surgical Ablation System (SAS). All of these devices are CE marked and received U.S. FDA 510(k) clearance. The REVELATION® Series of ablation catheters with the INTELLITEMP® EP Energy Management Device was developed and marketed for the treatment of atrial fibrillation (AF) after receiving CE mark approval in Europe; it is not currently available in the U.S.

For more information, please visit the Company's website at

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements. Potential risks and uncertainties include: the uncertainties associated with the prospects for FDA approval of any new devices; the prospect for any future clinical trials or regulatory activities; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure a strategic transaction involving the Surgical Ablation System. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, the Company's Quarterly Report on Form 10-QSB for the third quarter ended September 30, 2007, and in the Company's subsequent SEC filings. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact Information